doi: 10.1016/j.bmc.2006.09.019. Epub 2006 Oct 2.
Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists
Daniel P Walker 1, Donn G Wishka, David W Piotrowski, Shaojuan Jia, Steven C Reitz, Karen M Yates, Jason K Myers, Tatiana N Vetman, Brandon J Margolis, E Jon Jacobsen, Brad A Acker, Vincent E Groppi, Mark L Wolfe, Bruce A Thornburgh, Paula M Tinholt, Luz A Cortes-Burgos, Rodney R Walters, Matthew R Hester, Eric P Seest, Lester A Dolak, Fusen Han, Barbara A Olson, Laura Fitzgerald, Brian A Staton, Thomas J Raub, Mihaly Hajos, William E Hoffmann, Kai S Li, Nicole R Higdon, Theron M Wall, Raymond S Hurst, Erik H F Wong, Bruce N Rogers
Affiliations
- PMID:17011782
- DOI: 10.1016/j.bmc.2006.09.019
Item in Clipboard
Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists
Daniel P Walker et al. Bioorg Med Chem..
Display options
Format
Display options
Format
Abstract
A novel set of azabicyclic aryl amides have been identified as potent and selective agonists of the alpha7 nAChR. A two-pronged approach was taken to improve the potential hERG liability of previously disclosed alpha7 nAChR agonist, PNU-282,987, while maintaining the compound's other desirable pharmacological properties. The first approach involved further exploration of the aryl carboxylic acid fragment of PNU-282,987, while the second approach focused on modification of the azabicyclic amine portion of PNU-282,987. The best compounds from each series are characterized by rapid brain penetration, good oral bioavailability in rat, and demonstrate in vivo efficacy in a rat P50 auditory sensory gating assay. At least one analog from each series (1h, 1o, 2a, 9a, and 18a) shows an improved hERG safety profile over PNU-282,987.
Similar articles
- Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors.Bodnar AL, Cortes-Burgos LA, Cook KK, Dinh DM, Groppi VE, Hajos M, Higdon NR, Hoffmann WE, Hurst RS, Myers JK, Rogers BN, Wall TM, Wolfe ML, Wong E.Bodnar AL, et al.J Med Chem. 2005 Feb 24;48(4):905-8. doi: 10.1021/jm049363q.J Med Chem. 2005.PMID:15715459
- (R)-3'-(3-methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5'-oxazolidin]-2'-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties.Tatsumi R, Fujio M, Takanashi S, Numata A, Katayama J, Satoh H, Shiigi Y, Maeda J, Kuriyama M, Horikawa T, Murozono T, Hashimoto K, Tanaka H.Tatsumi R, et al.J Med Chem. 2006 Jul 13;49(14):4374-83. doi: 10.1021/jm060249c.J Med Chem. 2006.PMID:16821797
- Discovery of the alpha7 nicotinic acetylcholine receptor agonists. (R)-3'-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-[1',3']oxazolidin-2'-one as a novel, potent, selective, and orally bioavailable ligand.Tatsumi R, Fujio M, Satoh H, Katayama J, Takanashi S, Hashimoto K, Tanaka H.Tatsumi R, et al.J Med Chem. 2005 Apr 7;48(7):2678-86. doi: 10.1021/jm049188d.J Med Chem. 2005.PMID:15801858
- The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.Feuerbach D, Lingenhoehl K, Olpe HR, Vassout A, Gentsch C, Chaperon F, Nozulak J, Enz A, Bilbe G, McAllister K, Hoyer D.Feuerbach D, et al.Neuropharmacology. 2009 Jan;56(1):254-63. doi: 10.1016/j.neuropharm.2008.08.025. Epub 2008 Aug 28.Neuropharmacology. 2009.PMID:18793655
- Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, Hanchar AJ, Thornburgh BA, Cortes-Burgos LA, Wong EH, Staton BA, Raub TJ, Higdon NR, Wall TM, Hurst RS, Walters RR, Hoffmann WE, Hajos M, Franklin S, Carey G, Gold LH, Cook KK, Sands SB, Zhao SX, Soglia JR, Kalgutkar AS, Arneric SP, Rogers BN.Wishka DG, et al.J Med Chem. 2006 Jul 13;49(14):4425-36. doi: 10.1021/jm0602413.J Med Chem. 2006.PMID:16821801
Cited by
- Exploring chemical space for drug discovery using the chemical universe database.Reymond JL, Awale M.Reymond JL, et al.ACS Chem Neurosci. 2012 Sep 19;3(9):649-57. doi: 10.1021/cn3000422. Epub 2012 Apr 25.ACS Chem Neurosci. 2012.PMID:23019491Free PMC article.Review.
- Exploring α7-Nicotinic Receptor Ligand Diversity by Scaffold Enumeration from the Chemical Universe Database GDB.Garcia-Delgado N, Bertrand S, Nguyen KT, van Deursen R, Bertrand D, Reymond JL.Garcia-Delgado N, et al.ACS Med Chem Lett. 2010 Jul 20;1(8):422-6. doi: 10.1021/ml100125f. eCollection 2010 Nov 11.ACS Med Chem Lett. 2010.PMID:24900227Free PMC article.
- Stimulation of α7 nAChR leads to regeneration of damaged neurons in adult mammalian retinal disease models.Webster SE, Sklar NC, Spitsbergen JB, Stanchfield ML, Webster MK, Linn DM, Otteson DC, Linn CL.Webster SE, et al.Exp Eye Res. 2021 Sep;210:108717. doi: 10.1016/j.exer.2021.108717. Epub 2021 Aug 1.Exp Eye Res. 2021.PMID:34348130Free PMC article.
- Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration.Conejero-Goldberg C, Davies P, Ulloa L.Conejero-Goldberg C, et al.Neurosci Biobehav Rev. 2008;32(4):693-706. doi: 10.1016/j.neubiorev.2007.10.007. Epub 2007 Nov 28.Neurosci Biobehav Rev. 2008.PMID:18180036Free PMC article.Review.
- Efficient Synthesis of Hydroxy-Substituted 2-Aminobenzo[d]thiazole-6-carboxylic Acid Derivatives as New Building Blocks in Drug Discovery.Durcik M, Toplak Ž, Zidar N, Ilaš J, Zega A, Kikelj D, Mašič LP, Tomašič T.Durcik M, et al.ACS Omega. 2020 Mar 31;5(14):8305-8311. doi: 10.1021/acsomega.0c00768. eCollection 2020 Apr 14.ACS Omega. 2020.PMID:32309742Free PMC article.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials